Anebulo Pharmaceuticals, Inc. (ANEB)
0.3574
-0.03
(-8.36%)
USD |
OTCM |
Sep 09, 16:00
Anebulo Pharmaceuticals Enterprise Value : 5.642M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 5.642M |
| September 08, 2026 | 6.981M |
| September 04, 2026 | 5.691M |
| September 03, 2026 | 6.981M |
| September 02, 2026 | 3.284M |
| September 01, 2026 | 3.900M |
| August 31, 2026 | 3.900M |
| August 28, 2026 | 3.900M |
| August 27, 2026 | 4.516M |
| August 26, 2026 | 4.516M |
| August 25, 2026 | 4.516M |
| August 24, 2026 | 3.806M |
| August 21, 2026 | 4.516M |
| August 20, 2026 | 5.334M |
| August 19, 2026 | 5.334M |
| August 18, 2026 | 7.290M |
| August 17, 2026 | 8.214M |
| August 14, 2026 | 4.106M |
| August 13, 2026 | 3.284M |
| August 12, 2026 | 3.284M |
| August 11, 2026 | 3.284M |
| August 10, 2026 | 3.284M |
| August 07, 2026 | 3.465M |
| August 06, 2026 | 4.516M |
| August 05, 2026 | 4.516M |
| Date | Value |
|---|---|
| August 04, 2026 | 4.106M |
| August 03, 2026 | 4.106M |
| July 31, 2026 | 4.516M |
| July 30, 2026 | 4.516M |
| July 29, 2026 | 4.516M |
| July 28, 2026 | 4.516M |
| July 27, 2026 | 4.516M |
| July 24, 2026 | 3.284M |
| July 23, 2026 | 3.284M |
| July 22, 2026 | 3.284M |
| July 21, 2026 | 3.284M |
| July 20, 2026 | 4.496M |
| July 17, 2026 | 4.496M |
| July 16, 2026 | 4.516M |
| July 15, 2026 | -9.025M |
| July 14, 2026 | 4.779M |
| July 13, 2026 | 4.779M |
| July 10, 2026 | 4.779M |
| July 09, 2026 | 4.779M |
| July 08, 2026 | 4.779M |
| July 07, 2026 | 5.001M |
| July 06, 2026 | 6.078M |
| July 02, 2026 | 6.571M |
| July 01, 2026 | 6.571M |
| June 30, 2026 | 7.187M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.859B |
| Corcept Therapeutics, Inc. | 12.19B |
| Veru, Inc. | 19.18M |
| Johnson & Johnson | 671.47B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.999M |
| Total Expenses (Quarterly) | 1.999M |
| EPS Diluted (Quarterly) | -0.0487 |
| Earnings Yield | -54.34% |
| Normalized Earnings Yield | -54.34 |